Finasteride vs Minoxidil for Hair Loss: What the Evidence Actually Shows

Finasteride vs minoxidil: the short answer

Finasteride and minoxidil are the two best-established drug treatments for androgenetic alopecia (AGA), but they are not interchangeable, and the question "which is better" has no single answer. They work by different mechanisms: oral finasteride is a 5α-reductase inhibitor that counteracts the hormonal signal driving follicle miniaturization, while topical minoxidil is a vasodilator applied to the scalp ^{[2] [9]}. Both have "variable efficacy" and often require long-term adherence to keep any benefit ^[1]. No direct head-to-head trial between oral finasteride and topical minoxidil appears in the evidence reviewed here, so any claim that one simply beats the other overstates what the research shows.

What the evidence does support is a clear separation by route and regulatory status — which is exactly where most quick answers go wrong. Here is how the three main options actually compare:

What the evidence actually says about each option

Oral finasteride: the strongest hormonal evidence, with defined sexual risks

Oral finasteride 1 mg daily is FDA-approved specifically for male pattern hair loss, and the label is explicit that efficacy in bitemporal (temple) recession has not been established and that the drug is not indicated for women ^[9]. Across placebo-controlled RCTs of oral finasteride 1 mg in men with AGA, sexual adverse events were reported in 1.9–6.7% of treated patients versus 0.9–3.9% on placebo, with most events mild and reversible upon discontinuation ^[4]. The U.S. label reports year-one rates of decreased libido at 1.8%, erectile dysfunction at 1.3%, and ejaculation disorder at 1.2% versus lower placebo rates, and notes these incidences fell to ≤0.3% by the fifth year of treatment ^[9].

Two additional considerations matter for men weighing this option. Finasteride lowers serum PSA, which means any confirmed PSA rise while on the drug needs medical evaluation even if the value looks "normal" ^[9]. And 5α-reductase inhibitors may increase the risk of high-grade prostate cancer — shown with finasteride 5 mg in men 55 and over in a 7-year prevention trial (1.8% vs 1.1% placebo) ^[9]. A 2026 systematic review of 41 studies concluded that 5-ARIs are effective and generally well tolerated, but emphasized that individual susceptibility varies and that shared decision-making with a clinician is essential ^[4].

Topical minoxidil: the most accessible option, with a narrower approved use than people assume

Topical minoxidil 5% is available over the counter, but its FDA labeling is narrower than most online discussion suggests: it is approved to regrow hair on the top of the scalp (vertex only), for men, and the label states it is not intended for frontal baldness or a receding hairline ^[10]. The label is also candid that "this product will not work for all men," that results may occur at 2 months with twice-daily use, that some men need at least 4 months, and that continued use is necessary or hair loss will begin again ^[10].

On comparative efficacy, a 2026 systematic review with network meta-analyses of 23 studies ranked topical minoxidil 5% as the most effective option among the therapies compared, with topical melatonin, topical procyanidin, topical cetirizine, and topical finasteride among those showing potential benefit ^[3]. Reviews also note that minoxidil's clinical response is variable — some people appear to be non-responders, an issue attributed in part to follicular enzyme activity ^{[7] [1]}. Adjunct strategies exist but are not first-line: topical tretinoin may convert some minoxidil non-responders into responders, though one RCT found dual therapy no better than minoxidil alone and irritation is a real trade-off ^[7]. In women with mild-to-moderate AGA, a 24-week randomized trial of 245 women found microneedling added to 2% minoxidil provided no additional benefit over minoxidil alone ^[6].

Low-dose oral minoxidil: growing interest, off-label status, and a warning label worth reading

This is where conflating "minoxidil" causes the most confusion. Oral minoxidil is FDA-approved only for severe, treatment-resistant hypertension, and its labeling carries serious warnings: pericardial effusion (observed in about 3% of non-dialysis patients at treatment doses), salt and water retention requiring a diuretic, tachycardia usually requiring a beta-blocker, and exacerbation of angina ^[11]. The same label notes hypertrichosis — elongation and thickening of fine body hair — in about 80% of patients at hypertension doses, developing within 3 to 6 weeks ^[11]. That hypertrichosis effect is why low doses have been explored for hair disorders, but at hair-loss doses the drug remains off-label and no approved hair-loss label defines monitoring guidance ^[11].

The hair-specific evidence for low-dose oral minoxidil in this evidence base is limited and comes from outside male AGA. A prospective study of oral minoxidil 1 mg daily for 6 months in 11 women with frontal fibrosing alopecia (a scarring alopecia, not AGA) found improved hairline coverage in nine of ten completers and eyebrow improvement in four of eight, with mild hypertrichosis in five cases and one discontinuation due to a transient ischemic attack ^[8]. This is encouraging early data, not equivalent to the RCT base behind oral finasteride or topical minoxidil. If a clinician proposes low-dose oral minoxidil, the off-label status and the hypertension-label warnings are fair subjects for that conversation ^{[11] [8]}.

Can they be used together?

Combination approaches are an active research area. A phase 1 trial of a combined topical minoxidil–finasteride foam found it safe and well tolerated, with systemic finasteride exposure markedly lower than with oral administration — though this was a safety and pharmacokinetic study, not yet a demonstration of superior hair outcomes ^[5]. A broader review notes that platelet-rich plasma (PRP) has evidence of additive benefit when combined with traditional therapies, and that emerging agents may eventually complement or surpass current treatments, while cautioning that study heterogeneity limits firm comparisons ^[1]. Whether combining is right for any individual is a prescriber-level decision that depends on side-effect tolerance, and nothing here should be read as a recommendation to start or stack treatments.

Questions to bring to your clinician

• Is my hair loss actually androgenetic alopecia, and does its pattern match what each drug is approved or evidenced for — e.g., finasteride's temple-recession caveat, minoxidil's vertex-only label? ^{[9] [10]}
• Given my age, prostate-cancer screening plans, and PSA history, how should finasteride's PSA-lowering effect be managed? ^[9]
• What is my realistic timeline expectation, and at what point should we conclude a treatment isn't working for me? ^{[9] [10]}
• If I stop, what happens — and how does that affect my planning? (Finasteride's effect reverses within 12 months of withdrawal; minoxidil regrowth stops without continued use.) ^{[9] [10]}
• For low-dose oral minoxidil: what monitoring do you recommend given the hypertension-label warnings, and what is the evidence basis for my specific diagnosis? ^{[11] [8]}
• What sexual side effects should I watch for, how common are they in the controlled-trial data, and what should I do if I notice them? ^{[4] [9]}

What to track while you decide and treat

Because both drugs demand months of consistent use before benefit appears — three months or more for finasteride, two to four months for topical minoxidil — objective tracking matters more than mirror-checking ^{[9] [10]}. Take standardized baseline photos before starting anything, then repeat them on a fixed schedule rather than daily. A neutral check-in schedule removes the temptation to judge progress from ambiguous snapshots, and a side-by-side comparison of two photos taken months apart under matching conditions is far more informative than memory. Log the date you started or changed anything, since "did it work?" is only answerable relative to a known baseline. All of this is exactly what our Photo Protocol, Check-in Schedule, and Comparison Studio tools are built for.

Frequently asked questions

Is finasteride stronger than minoxidil?

There is no valid head-to-head answer in the reviewed evidence. They act by different mechanisms, are approved for different uses, and individual response varies with both ^{[2] [3] [9]}.

Which works faster?

Topical minoxidil's label says results may occur at 2 months, sometimes needing 4; finasteride's label says three months or more of daily use is generally needed before benefit is observed ^{[10] [9]}.

Does finasteride have sexual side effects?

In controlled trials, 1.9–6.7% of men on oral finasteride 1 mg reported sexual adverse events vs 0.9–3.9% on placebo; most were mild and reversible after stopping ^{[4] [9]}.

Is oral minoxidil approved for hair loss?

No. Oral minoxidil is FDA-approved only for severe hypertension; its use for hair loss is off-label and its label carries serious warnings at labeled doses, including pericardial effusion and fluid retention ^[11].

Can women use finasteride or minoxidil?

Oral finasteride is not indicated for women, and pregnant women should not handle crushed or broken tablets ^[9]. The 5% topical minoxidil product described here is labeled for men only ^[10]; women with hair loss should ask a clinician which options apply to them.